Business News • PR NewsWire • Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies

Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies

Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies

PARAMUS, N.J., Jan. 27, 2020 /PRNewswire/ -- Epygenix Therapeutics, Inc., a privately held biopharmaceutical company developing precision medicine for Dravet Syndrome, announced today that the Company successfully completed a Phase I, Placebo-Controlled, Double-Blind, 2-Period Study to...

View More : https://www.prnewswire.com:443/news-releases/epygenix-therapeutics-successfully-completes-epx-100-phase-i-placebo-contro...

Releted News by prnewswire

CV SCIENCES INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CV Sciences, Inc. - CVSI

Maine Inn Announces Contest

'HANDMAID'S TALE,' 'VEEP,' 'JOJO RABBIT' And 'BEAUTIFUL DAY' Are Among Winners Of 45th HUMANITAS Prize

Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies

Buddhist Leader's Annual Peace Proposal Applauds Youth Climate Action and Promotes Nuclear Weapons Treaty

Weltberühmter Polostar Ignacio „Nacho" Figueras als Markenbotschafter für Saudi-Arabiens Ultra-Luxus-Resort AMAALA enthüllt